Subscribe To
Tg therapeutics: things are stacking up against briumvi
TG Therapeutics, Inc. stock has declined by 75% since its approval highs, with little hope of recovery. The company's fortunes have been tied to its e...
October 16, 2023, 4:47 pm
Tg therapeutics: racing against time while their differentiators are still relevant
TG Therapeutics has transitioned from a developer of oncology drugs to a commercial-stage neurology company with the approval of its multiple sclerosi...
October 3, 2023, 2:26 pm
Why is tg therapeutics (tgtx) stock down 50% today?
Following a disappointing outcome for the second quarter, shares of biotechnology firm TG Therapeutics (NASDAQ: TGTX ) suffered a catastrophic loss. S...
August 1, 2023, 12:56 pm
Tg therapeutics: addressing the sc ocrevus concern
The launch of briumvi is off to a solid start, but the stock pulled back recently and fell more after R...
July 29, 2023, 9:50 pm
Ocrevus challenges briumvi: a closer look at tg therapeutics' position
TG Therapeutics, Inc.'s Briumvi, a treatment for multiple sclerosis, faces competition from Roche's Ocrevus, which has shown positive results in a Pha...
July 13, 2023, 5:49 pm
Tg therapeutics: recent progress of briumvi builds up momentum
Partial sales of TG Therapeutics, Inc.'s briumvi for Relapsing forms of multiple sclerosis reached $7.8...
July 5, 2023, 7:06 pm
Tg therapeutics: a buy for its monster multiple sclerosis agent
New earning asset briumvi launched in February and got approved in Europe. ...
June 15, 2023, 3:33 am
Tg therapeutics announces presentation of data from the ultimate i & ii phase 3 trials of briumvi® (ublituximab-xiiy) in multiple sclerosis at the 2023 consortium of multiple sclerosis centers annual
NEW YORK, June 02, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the ULTIMATE I & II P...
June 2, 2023, 1:15 pm
Tg therapeutics announces data from the ultimate i & ii phase 3 trials of briumvi® (ublituximab-xiiy) in multiple sclerosis to be presented at the 2023 consortium of multiple sclerosis centers annual
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the details of an upcoming oral presentation, highli...
May 31, 2023, 11:30 am
Why shares of tg therapeutics soared on tuesday
The company launched multiple sclerosis drug briumvi on Jan. 26. The drug reportedly has already had ne...
April 11, 2023, 1:49 pm
Top-notch biotech tg therapeutics logs 'solid jump' in sales; shares rocket
TG Therapeutics' new MS drug, Briumvi, experienced a "solid jump" in March sales, according to a report. TGTX stock flew on Monday....
April 10, 2023, 1:23 pm
Tg therapeutics announces positive chmp opinion for briumvi™ (ublituximab-xiiy) for the treatment of relapsing forms of multiple sclerosis in adults
NEW YORK, March 31, 2023 (GLOBE NEWSWIRE) — TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the Committee for Medicinal Products for Huma...
March 31, 2023, 11:30 am
Tg therapeutics: that icer report doesn't bother me
ICER published a report saying TG Therapeutics, Inc.'s briumvi is overpriced. It has said this for othe...
March 20, 2023, 1:25 pm
Tg therapeutics: strategy after briumvi launch
After a year of churn and doldrums, TG Therapeutics, Inc. finally got approval for, and launched, briumvi ...
February 1, 2023, 12:22 pm
Tg therapeutics: ramifications of briumvi approval
TG Therapeutics, Inc. is set to launch briumvi with an experienced in-house team. There are several fac...
January 2, 2023, 1:04 pm
Tg therapeutics (tgtx) gets fda nod for multiple sclerosis drug
The FDA approves TG Therapeutics' (TGTX) briumvi (ublituximab-xiiy) for treating relapsing forms of mul...
December 29, 2022, 12:02 pm
Tg therapeutics announces fda approval of briumvi™ (ublituximab-xiiy)
briumvi is the first and only anti-CD20 monoclonal antibody approved for patients with relapsing forms ...
December 28, 2022, 6:48 pm
Tg therapeutics: ublituximab could achieve $1 billion in annual sales by year-end 2024
TG Therapeutics is approaching its Prescription Drug User Fee Act (PDUFA) goal date of December 28, 2022, for ublituximab for the treatment of relapsi...
December 15, 2022, 2:04 pm